Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

CAS：69004-04-2
中文别名：托曲珠利砜;1-甲基-3-{3-甲基-4-[4-(三氟甲基磺酰)苯氧基]苯基}-1,3,5-三嗪-2,4,6(1H,3H,5H)-三酮;
英文别名：Toltrazuril sulfone;1-methyl-3-[3-methyl-4-(4-trifluoromethanesulfonyl-phenoxy)-phenyl]-[1,3,5]triazinane-2,4,6-trione;Ponazuril;Marquis;toltrazuril;Ponazuril [INN];1-Methyl-3-{3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl}-1,3,5-triazine-2,4,6(1H,3H,5H)-trione;UNII-JPW84AS66U;
分子式：C18H14F3N3O6S
分子量：457.38
精确质量：457.056
Psa：128.61
Logp：2.6995

MDL号：MFCD09263475

密度：1.507g/cm3
折射率：1.572